This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sumitomo Dainippon Pharma Co., Ltd.
Drug Names(s): SEP-162
Description: SEP-227162 is a serotonin and norepinephrine reuptake inhibitor (SNRI). Serotonin and norepinephrine are two neurotransmitters that are thought to play important roles in the pathophysiology of depression.
Deal Structure: SEP-227162 was originally developed by Sepracor.
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share. The acquisition was completed in October 2009.
Pink Sheet Sepracor Surges Amid Dainippon Takeover Talk
Additional information available to subscribers only: